|

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

RECRUITINGN/ASponsored by Lahey Clinic
Actively Recruiting
PhaseN/A
SponsorLahey Clinic
Started2025-01-01
Est. completion2029-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07187063

Summary

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* AUA high-risk bladder cancer1
* Received induction BCG or gemcitabine/docetaxel
* Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)

Exclusion Criteria:

* High-risk NMIBC within 3 years
* Prior induction intravesical therapy
* Variant histology
* Concurrent upper tract disease

Conditions2

CancerNon-muscle Invasive Bladder Cancer (NMIBC)

Locations1 site

Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Linda Topjian7817448711linda.m.topjian@lahey.org

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.